“A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting”, J. Can. Res. Updates, vol. 12, pp. 49–53, Dec. 2023, doi: 10.30683/1929-2279.2023.12.9.